查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
药物动力学服务市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按药物类型、服务类型、治疗应用、最终用户和地理位置
市场调查报告书
商品编码
1498540

药物动力学服务市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按药物类型、服务类型、治疗应用、最终用户和地理位置

Pharmacokinetics Services Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Type, Service Type, Therapeutic Application, and End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 174 Pages | 订单完成后即时交付

价格

药物动力学服务市场规模预计将从 2023 年的 8.7496 亿美元增至 2031 年的 15.7987 亿美元。

药物动力学服务市场的市场驱动因素

慢性病和传染病的盛行率上升

糖尿病、癌症和自体免疫疾病等慢性病的日益普及一直是全世界药物开发工作的主要动力。根据世界卫生组织（WHO）2024年的资料，全球约有4.22亿人患有糖尿病，这些病例大多发生在中低收入国家，每年导致约150万人死亡。製药公司处于开发治疗各种疾病药物的前沿。药物动力学研究对于透过分析人体内吸收、分布、代谢和消除 (ADME) 的过程来了解这些药物在患者体内的行为至关重要。药物吸收到体循环中影响药物到达作用部位（例如血浆）的速度和浓度。药物在全身的分布模式会根据其生化特性和身体生理而改变。代谢涉及身体将药物加工成后续化合物。此步骤有助于将药物转化为水溶性物质，使其适合肾臟清除。代谢对于将可待因等前药转化为活性代谢物也很重要。体内药物的排泄主要受肾臟支配；然而，在某些情况下，药物可能会经由肺部、皮肤或胃肠道排泄。 ADME 动力学定义了药物在体内的生物利用度，药物的维持剂量是根据其清除时间（所需血浆浓度除以生物利用度）计算的。了解清除率可以帮助从业人员计算适当的剂量率。

药物动力学研究的重点是优化研究对象的药物剂量方案，以了解药物的功效和安全性。这些研究对于确保长期治疗药物的安全性至关重要，有助于评估药物配方在慢性病管理中的适用性和稳定性。因此，慢性病和传染病负担的增加凸显了药物动力学研究对于开发安全有效的个人化治疗的重要性。

药物动力学服务市场的机会

收集和处理药物製造过程中产生的大量药物动力学资料是一项昂贵、繁琐且耗时的任务。这些任务的劳动力和成本密集性质凸显了对用于预测药物动力学参数的药物动力学模拟模型和体外-体内药物动力学相关模型（IVIVC）等模型的需求。药物动力学模拟模型是利用计算和数学模型解释特定条件下生活环境中药物动力学的工具。此外，IVIVC 模型是药物发现过程的基本组成部分。在药物开发的早期阶段分析 PK/PD 预测对于先导优化策略和进一步降低损耗率是必要的。在开发新的体外和体内策略以改善和表征药物动力学特性方面取得了重大进展。 IVIVC 模型被提议作为一种经济高效的替代方案，用于评估生物製药特性，分析药物的生物利用度及其应用。因此，预计此类体内和体外模型将在不久的将来为药物动力学服务市场提供利润丰厚的机会。

药物动力学服务市场：细分概述

依药物类型划分，市场分为小分子、大分子和疫苗。 2023 年，小分子细分市场占据最大的市场份额。

药物动力学服务市场依治疗应用分为肿瘤学、传染病、神经系统疾病、自体免疫疾病、妇科疾病、心血管疾病、呼吸系统疾病等。 2023 年，肿瘤学领域占据最大的市场份额。

药物动力学服务市场：地理概述

北美占据最大的市场份额。根据加拿大政府的报告，加拿大卫生部收到了数百份新的临床试验申请，以测试新药（包括疫苗）或引入已批准药物的新用途。该国的儿科患者（儿童和青少年）在父母许可的情况下参加临床试验。加拿大卫生部保护参与临床试验的个人，包括儿童和青少年。根据加拿大临床试验资产图 (CCTAM) 报告，2022 年加拿大註册了约 3,500 项临床试验，其中癌症治疗是一个重要的重点领域，2021 年有 1,300 项癌症临床试验。创新药物局的报告，加拿大的临床研究投入了12 亿美元。此外，截至 2021 年，加拿大临床试验网络 (CCTN) 保存了超过 600 万笔病患记录。因此，临床试验和研究数量的增加以及传染病和慢性疾病盛行率的增加是推动加拿大药物动力学服务市场成长的因素。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：药物动力学服务市场格局

  • PEST分析

第 5 章：药物动力学服务市场 - 主要市场动态

  • 药物动力学服务市场 - 主要市场动态
  • 市场驱动因素
    • 慢性病和传染病的盛行率上升
    • 扩大药物动力学研究的应用范围
    • 将药物动力学服务外包给 CRO
  • 市场限制
    • 新兴国家药物动力学服务提供者的覆盖范围有限
  • 市场机会
    • 越来越多地采用体内和体外模型来了解药物动力学的变异性
  • 未来趋势
    • 药物动力学服务中越来越多采用大数据分析
  • 驱动因素和限制的影响：

第 6 章：药物动力学服务市场 - 全球市场分析

  • 药物动力学服务市场收入，2023-2031

第 7 章：药物动力学服务市场分析 - 按药物类型

  • 概述
  • 小分子
  • 大分子
  • 疫苗

第 8 章：药物动力学服务市场分析 - 按服务类型

  • 临床前 ADME 和人体研究
  • PK/PD 分析和报告
  • 剂量模拟
  • 风险分析
  • 其他的

第 9 章：药物动力学服务市场分析 - 按治疗应用

  • 肿瘤学
  • 传染性疾病
  • 神经系统疾病
  • 自体免疫疾病
  • 妇科疾病
  • 心血管疾病
  • 呼吸系统疾病
  • 其他的

第 10 章：药物动力学服务市场分析 - 按最终用户

  • 製药和生物技术公司
  • 合约研究组织
  • 其他的

第 11 章：药物动力学服务市场 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国

到 2031 年，传染病领域的市场预计价值 1,924 万美元，预计 2023-2031 年复合年增长率为 10.8%。

      • 英国：药物动力学服务市场 - 收入和 2031 年预测
      • 义大利：药物动力学服务市场 - 收入和 2031 年预测
      • 西班牙：药物动力学服务市场 - 收入和 2031 年预测
      • 欧洲其他地区：药物动力学服务市场 - 收入和 2031 年预测
  • 亚太地区
    • 亚太地区药物动力学服务市场概况
    • 亚太地区：药物动力学服务市场
    • 亚太地区：药物动力学服务市场 - 收入和预测分析 - 按国家/地区
      • 中国：药物动力学服务市场 - 收入及 2031 年预测
      • 日本：药物动力学服务市场 - 收入和 2031 年预测
      • 印度：药物动力学服务市场 - 收入和 2031 年预测
      • 澳洲：药物动力学服务市场 - 收入和 2031 年预测
      • 韩国：药物动力学服务市场 - 收入和 2031 年预测
      • 亚太地区其他地区：药物动力学服务市场 - 收入和 2031 年预测
  • 中东和非洲
    • 中东和非洲药物动力学服务市场概况
    • 中东和非洲：药物动力学服务市场 - 收入和 2031 年预测
    • 按国家/地区分類的药物动力学服务市场细分
    • 药物动力学服务市场收入、预测与分析 - 按国家/地区
    • 中东和非洲：药物动力学服务市场 - 收入和预测分析 - 按国家/地区
      • 沙乌地阿拉伯：药物动力学服务市场 - 收入和 2031 年预测
      • 南非：药物动力学服务市场 - 收入和 2031 年预测
      • 阿拉伯联合大公国：药物动力学服务市场 - 收入和 2031 年预测
      • 中东和非洲其他地区：药物动力学服务市场 - 收入和 2031 年预测
  • 南美洲和中美洲
    • 南美洲和中美洲药物动力学服务市场概述
    • 南美洲和中美洲：药物动力学服务市场 - 收入和 2031 年预测
    • 按国家/地区分類的药物动力学服务市场细分
    • 药物动力学服务市场收入、预测与分析 - 按国家/地区
      • 巴西：药物动力学服务市场 - 收入和 2031 年预测
      • 阿根廷：药物动力学服务市场 - 收入和 2031 年预测
      • 南美洲和中美洲其他地区：药物动力学服务市场 - 收入和 2031 年预测

第 12 章：公司简介

  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • Evotec SE
  • Certara Inc.
  • Parexel International Corp
  • Thermo Fisher Scientific Inc.
  • Allucent
  • PACIFIC BIOLABS
  • SGS SA
  • Shanghai Medicilon Inc.

第 13 章：附录

Product Code: TIPRE00007438

The pharmacokinetics services market size is projected to reach US$ 1,579.87 million by 2031 from US$ 874.96 million in 2023. The market is expected to register a CAGR of 7.6% during 2023-2031.

Market Drivers of the Pharmacokinetics Services Market

Rising Prevalence of Chronic and Infectious Diseases

The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune diseases has been a prime enabler of drug development efforts across the world. According to the World Health Organization's (WHO) 2024 data, ~422 million in the world suffer from diabetes, and these cases are mostly found in middle and low-income countries, causing approximately 1.5 million deaths every year. Pharmaceutical companies are at the forefront of developing drugs to treat various diseases. Pharmacokinetic studies are essential for understanding how these drugs behave in a patient's body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body. The absorption of a drug into systemic circulation affects the speed and concentration at which a drug may reach the site of action, e.g., plasma. Drug distribution pattern throughout the body varies based on its biochemical properties and body physiology. Metabolism involves the processing of the drug by the body into subsequent compounds. This step is instrumental in converting the drug into water-soluble substances to render them suitable for renal clearance. Metabolism is also important for the conversion of prodrugs, such as codeine, into active metabolites. Excretion of drugs from the body is mainly governed by kidneys; however, in several cases, drugs may be excreted via the lungs, skin, or gastrointestinal tract. ADME dynamics define the bioavailability of drugs in the body, and the maintenance doses of drugs are calculated based on their clearance times (desired plasma concentration divided by bioavailability). Understanding of clearance allows practitioners to calculate appropriate dosing rates.

Pharmacokinetic studies focus on optimizing drug dose regimens in study subjects to understand the efficacy and safety of a drug. These studies are essential for ensuring the safety of drugs that are developed for long-term treatments, which helps evaluate the suitability and stability of drug formulations in chronic disease management. Hence, the rising burden of chronic and infectious diseases underlines the importance of pharmacokinetic studies to develop safe and effective personalized treatments.

Opportunities in the Pharmacokinetics Services Market

The collection and handling of huge pharmacokinetic data generated during drug manufacturing are expensive, tedious, and time-consuming tasks. The labor- and cost-intensive nature of these tasks highlights the need for models such as pharmacokinetic simulation models and in vitro-in vivo pharmacokinetic correlation models (IVIVC) for the prediction of pharmacokinetic parameters. The pharmacokinetic simulation model is a tool that interprets drug kinetics in the living environment under specific conditions using computational and mathematical models. In addition, the IVIVC model are a fundamental part of the drug discovery process. Analyzing PK/PD predictions at the early stages of drug development is necessary for lead optimization strategies and also to further reduce attrition rates. There have been significant advancements in the development of new in-vitro and in-vivo strategies to improve and characterize pharmacokinetic properties. IVIVC models are being proposed as a cost-effective alternative to assess the biopharmaceutical properties that analyze the bioavailability of drugs and their application. Hence, such in-vivo and in-vitro models are anticipated to provide lucrative opportunities for the pharmacokinetics services market in the near future.

Pharmacokinetics Services Market: Segmental Overview

By drug type, the market is segmented into small molecules, large molecules, and vaccines. The small molecule segment held the largest market share in 2023.

The pharmacokinetics services market, by therapeutic application, is categorized into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

Pharmacokinetics Services Market: Geographical Overview

North America held the largest share of the market. According to a report by the Government of Canada, Health Canada receives hundreds of new clinical trial applications to test new drugs (including vaccines) or to introduce new uses of approved medicines. Pediatric patients (children and youth) in the country participate in clinical trials with their parents' permission. Health Canada protects individuals participating in clinical trials, including children and youth. According to the Canadian Clinical Trials Asset Map (CCTAM) report, ~3,500 clinical trials were registered in Canada in 2022, with cancer therapeutics being a significant area of focus, accounting for 1,300 cancer clinical trials in 2021. The pharmaceutical industry invested ~US$ 1.2 billion in clinical research in Canada, per the Innovative Medicines Canada report. Further, the Canadian Clinical Trials Network (CCTN) had over 6 million patient records maintained as of 2021. Thus, the demand for pharmacokinetic services increases with the surge in drug development and discovery projects in Canada. Thus, the rising number of clinical trials and research studies, and the increasing prevalence of infectious diseases and chronic disorders are among the factors propelling the pharmacokinetics services market growth in Canada.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Pharmacokinetics Services Market Landscape

  • 4.1 PEST Analysis

5. Pharmacokinetics Services Market - Key Market Dynamics

  • 5.1 Pharmacokinetics Services Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic and Infectious Diseases
    • 5.2.2 Expanding Range of Application of Pharmacokinetic Studies
    • 5.2.3 Outsourcing of Pharmacokinetics Services to CROs
  • 5.3 Market Restraints
    • 5.3.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
  • 5.4 Market Opportunities
    • 5.4.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
  • 5.5 Future Trend
    • 5.5.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
  • 5.6 Impact of Drivers and Restraints:

6. Pharmacokinetics Services Market - Global Market Analysis

  • 6.1 Pharmacokinetics Services Market Revenue (US$ Million), 2023-2031

7. Pharmacokinetics Services Market Analysis - by Drug Type

  • 7.1 Overview
  • 7.2 Small Molecule
    • 7.2.1 Overview
    • 7.2.2 Small Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Large Molecule
    • 7.3.1 Overview
    • 7.3.2 Large Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Vaccines
    • 7.4.1 Overview
    • 7.4.2 Vaccines: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Pharmacokinetics Services Market Analysis - by Service Type

  • 8.1 Pre-Clinical ADME and Human Studies
    • 8.1.1 Overview
    • 8.1.2 Pre-Clinical ADME and Human Studies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 PK/PD Analysis and Reporting
    • 8.2.1 Overview
    • 8.2.2 PK/PD Analysis and Reporting: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Dosing Simulations
    • 8.3.1 Overview
    • 8.3.2 Dosing Simulations: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Risk Analysis
    • 8.4.1 Overview
    • 8.4.2 Risk Analysis: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Pharmacokinetics Services Market Analysis - by Therapeutic Application

  • 9.1 Oncology
    • 9.1.1 Overview
    • 9.1.2 Oncology: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Infectious Diseases
    • 9.2.1 Overview
    • 9.2.2 Infectious Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Neurological Disorders
    • 9.3.1 Overview
    • 9.3.2 Neurological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Autoimmune Diseases
    • 9.4.1 Overview
    • 9.4.2 Autoimmune Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Gynecological Disorders
    • 9.5.1 Overview
    • 9.5.2 Gynecological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.6 Cardiovascular Diseases
    • 9.6.1 Overview
    • 9.6.2 Cardiovascular Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.7 Respiratory Disorders
    • 9.7.1 Overview
    • 9.7.2 Respiratory Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.8 Others
    • 9.8.1 Overview
    • 9.8.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Pharmacokinetics Services Market Analysis - by End User

  • 10.1 Pharmaceutical and Biotechnology Companies
    • 10.1.1 Overview
    • 10.1.2 Pharmaceutical and Biotechnology Companies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Contract Research Organization
    • 10.2.1 Overview
    • 10.2.2 Contract Research Organization: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Others
    • 10.3.1 Overview
    • 10.3.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11. Pharmacokinetics Services Market - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Pharmacokinetics Services Market Overview
    • 11.1.2 North America: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
      • 11.1.2.1 United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.1.1 Overview
        • 11.1.2.1.2 United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.1.3 United States: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.2.1.4 United States: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.2.1.5 United States: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.2.1.6 United States: Pharmacokinetics Services Market Breakdown, by End User
      • 11.1.2.2 Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.2.1 Overview
        • 11.1.2.2.2 Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.2.3 Canada: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.2.2.4 Canada: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.2.2.5 Canada: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.2.2.6 Canada: Pharmacokinetics Services Market Breakdown, by End User
      • 11.1.2.3 Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.3.1 Overview
        • 11.1.2.3.2 Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.3.3 Mexico: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.1.2.3.4 Mexico: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.1.2.3.5 Mexico: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.1.2.3.6 Mexico: Pharmacokinetics Services Market Breakdown, by End User
  • 11.2 Europe
    • 11.2.1 Europe Pharmacokinetics Services Market Overview
    • 11.2.2 Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.2.3 Pharmacokinetics Services Market Breakdown by Countries
    • 11.2.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
      • 11.2.4.1 Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.1.1 Overview
        • 11.2.4.1.2 Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.1.3 Germany: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.1.4 Germany: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.1.5 Germany: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.2.4.1.6 Germany: Pharmacokinetics Services Market Breakdown, by End User
      • 11.2.4.2 France: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.2.1 Overview
        • 11.2.4.2.2 France: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.2.3 France: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.2.4 France: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.2.5 France: Pharmacokinetics Services Market Breakdown, by Therapeutic Application

The market for infectious diseases segment is estimated to be worth US$ 19.24 million by 2031 and is expected to register a CAGR of 10.8% during the 2023-2031.

        • 11.2.4.2.6 France: Pharmacokinetics Services Market Breakdown, by End User
      • 11.2.4.3 United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.3.1 Overview
        • 11.2.4.3.2 United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.3.3 United Kingdom: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.3.4 United Kingdom: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.3.5 United Kingdom: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.2.4.3.6 United Kingdom: Pharmacokinetics Services Market Breakdown, by End User
      • 11.2.4.4 Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.4.1 Overview
        • 11.2.4.4.2 Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.4.3 Italy: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.4.4 Italy: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.4.5 Italy: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.2.4.4.6 Italy: Pharmacokinetics Services Market Breakdown, by End User
      • 11.2.4.5 Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.5.1 Overview
        • 11.2.4.5.2 Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.5.3 Spain: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.5.4 Spain: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.5.5 Spain: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.2.4.5.6 Spain: Pharmacokinetics Services Market Breakdown, by End User
      • 11.2.4.6 Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.6.1 Overview
        • 11.2.4.6.2 Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.4.6.3 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.2.4.6.4 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.2.4.6.5 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.2.4.6.6 Rest of Europe: Pharmacokinetics Services Market Breakdown, by End User
  • 11.3 Asia Pacific
    • 11.3.1 Asia Pacific Pharmacokinetics Services Market Overview
    • 11.3.2 Asia Pacific: Pharmacokinetics Services Market
    • 11.3.3 Asia Pacific: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
      • 11.3.3.1 China: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.1.1 Overview
        • 11.3.3.1.2 China: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.1.3 China: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.1.4 China: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.1.5 China: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.1.6 China: Pharmacokinetics Services Market Breakdown, by End User
      • 11.3.3.2 Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.2.1 Overview
        • 11.3.3.2.2 Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.2.3 Japan: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.2.4 Japan: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.2.5 Japan: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.2.6 Japan: Pharmacokinetics Services Market Breakdown, by End User
      • 11.3.3.3 India: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.3.1 Overview
        • 11.3.3.3.2 India: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.3.3 India: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.3.4 India: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.3.5 India: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.3.6 India: Pharmacokinetics Services Market Breakdown, by End User
      • 11.3.3.4 Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.4.1 Overview
        • 11.3.3.4.2 Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.4.3 Australia: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.4.4 Australia: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.4.5 Australia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.4.6 Australia: Pharmacokinetics Services Market Breakdown, by End User
      • 11.3.3.5 South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.5.1 Overview
        • 11.3.3.5.2 South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.5.3 South Korea: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.5.4 South Korea: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.5.5 South Korea: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.5.6 South Korea: Pharmacokinetics Services Market Breakdown, by End User
      • 11.3.3.6 Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.6.1 Overview
        • 11.3.3.6.2 Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.6.3 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.3.3.6.4 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.3.3.6.5 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.3.3.6.6 Rest of APAC: Pharmacokinetics Services Market Breakdown, by End User
  • 11.4 Middle East and Africa
    • 11.4.1 Middle East and Africa Pharmacokinetics Services Market Overview
    • 11.4.2 Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.4.3 Pharmacokinetics Services Market Breakdown by Countries
    • 11.4.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
    • 11.4.5 Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
      • 11.4.5.1 Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.1.1 Overview
        • 11.4.5.1.2 Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.1.3 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.4.5.1.4 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.4.5.1.5 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.4.5.1.6 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by End User
      • 11.4.5.2 South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.2.1 Overview
        • 11.4.5.2.2 South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.2.3 South Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.4.5.2.4 South Africa: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.4.5.2.5 South Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.4.5.2.6 South Africa: Pharmacokinetics Services Market Breakdown, by End User
      • 11.4.5.3 United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.3.1 Overview
        • 11.4.5.3.2 United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.3.3 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.4.5.3.4 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.4.5.3.5 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.4.5.3.6 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by End User
      • 11.4.5.4 Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.4.1 Overview
        • 11.4.5.4.2 Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.5.4.3 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.4.5.4.4 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.4.5.4.5 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.4.5.4.6 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by End User
  • 11.5 South and Central America
    • 11.5.1 South and Central America Pharmacokinetics Services Market Overview
    • 11.5.2 South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.5.3 Pharmacokinetics Services Market Breakdown by Countries
    • 11.5.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
      • 11.5.4.1 Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.1.1 Overview
        • 11.5.4.1.2 Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.1.3 Brazil: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.5.4.1.4 Brazil: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.5.4.1.5 Brazil: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.5.4.1.6 Brazil: Pharmacokinetics Services Market Breakdown, by End User
      • 11.5.4.2 Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.2.1 Overview
        • 11.5.4.2.2 Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.2.3 Argentina: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.5.4.2.4 Argentina: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.5.4.2.5 Argentina: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.5.4.2.6 Argentina: Pharmacokinetics Services Market Breakdown, by End User
      • 11.5.4.3 Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.3.1 Overview
        • 11.5.4.3.2 Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.4.3.3 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Drug Type
        • 11.5.4.3.4 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Service Type
        • 11.5.4.3.5 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 11.5.4.3.6 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by End User

12. Company Profile

  • 12.1 Charles River Laboratories International Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Eurofins Scientific SE
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Evotec SE
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Certara Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
  • 12.5 Parexel International Corp
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Thermo Fisher Scientific Inc.
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Allucent
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 PACIFIC BIOLABS
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 SGS SA
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Shanghai Medicilon Inc.
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners

List Of Tables

  • Table 1. Pharmacokinetics Services Market Segmentation
  • Table 2. United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 3. United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 4. United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 5. United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 6. Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 7. Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 8. Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 9. Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 10. Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 11. Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 12. Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 13. Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 14. Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 15. Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 16. Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 17. Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 18. France: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 19. France: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 20. France: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 21. France: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 22. United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 23. United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 24. United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 25. United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 26. Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 27. Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 28. Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 29. Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 30. Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 31. Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 32. Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 33. Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 34. Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 35. Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 36. Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 37. Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 38. China: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 39. China: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 40. China: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 41. China: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 42. Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 43. Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 44. Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 45. Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 46. R&D Expenditure of Indian Companies, 2018-2020 (US$ Million)
  • Table 47. Company
  • Table 48. India: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 49. India: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 50. India: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 51. India: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 52. Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 53. Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 54. Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 55. Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 56. South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 57. South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 58. South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 59. South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 60. Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 61. Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 62. Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 63. Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 64. Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 65. Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 66. Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 67. Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 68. South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 69. South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 70. South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 71. South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 72. United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 73. United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 74. United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 75. United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 76. Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 77. Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 78. Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 79. Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 80. Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 81. Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 82. Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 83. Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 84. Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 85. Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 86. Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 87. Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 88. Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Drug Type
  • Table 89. Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Service Type
  • Table 90. Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic Application
  • Table 91. Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million) - by End User

List Of Figures

  • Figure 1. Pharmacokinetics Services Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Pharmacokinetics Services Market Revenue (US$ Million), 2023-2031
  • Figure 5. Pharmacokinetics Services Market, By Geography Forecast Analysis, 2023 & 2031
  • Figure 6. Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
  • Figure 7. Small Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Large Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Vaccines: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
  • Figure 11. Pre-Clinical ADME and Human Studies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. PK/PD Analysis and Reporting: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Dosing Simulations: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Risk Analysis: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
  • Figure 17. Oncology: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Infectious Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Neurological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Autoimmune Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Gynecological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Cardiovascular Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Respiratory Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
  • Figure 26. Pharmaceutical and Biotechnology Companies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Contract Research Organization: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. North America: Pharmacokinetics Services Market by Key Countries - Revenue (2023) US$ Million
  • Figure 30. North America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. North America: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 32. United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. Europe: Pharmacokinetics Services Market - Revenue by Key Countries Revenue 2023 (US$ Million)
  • Figure 36. Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 37. Europe: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 38. Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. France: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. Asia Pacific: Pharmacokinetics Services Market - Revenue by Key Countries 2023 (US$ Million)
  • Figure 45. Asia Pacific: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. Asia Pacific: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 47. China: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 48. Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. India: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 50. Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Middle East and Africa: Pharmacokinetics Services Market by Key Countries - Revenue 2023 (US$ Million)
  • Figure 54. Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. Pharmacokinetics Services Market Breakdown by Key Countries, 2023 and 2031 (%)
  • Figure 56. Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 57. Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 58. South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 60. Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 61. South and Central America: Pharmacokinetics Services Market by Key Countries - Revenue 2023 (US$ Million)
  • Figure 62. South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 63. Pharmacokinetics Services Market Breakdown by Key Countries, 2023 and 2031 (%)
  • Figure 64. Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 65. Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 66. Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)